French medtech company Raidium, a pioneer in precision radiology, has successfully raised $13 million in seed funding. This round was led by Newfund, known for its investments in companies like Ramify and Kurma, with additional contributions from Founders Future, Galion.exe, and the European EIC fund.
Scaling Up and Expanding Horizons
Raidium aims to leverage this funding to accelerate the global adoption of its innovative technology. The company plans to establish a presence in the United States by opening new offices, enabling closer collaboration with partners and clients. Simultaneously, it will enhance its European operations and pursue critical regulatory approvals, including FDAand CE certifications.
To fuel innovation, Raidium will intensify its R&D activities, focusing on expanding its multimodal capabilities. Over the coming months, the startup will double its workforce, recruiting 25 new team members in areas like research, development, regulatory compliance, and commercial partnerships.
Addressing the Urgent Need for Precision Diagnostics
Precision diagnostics are becoming increasingly crucial, yet radiologists often struggle with outdated tools that impede both accuracy and efficiency. With the rising complexity of imaging modalities like MRIs and CT scans, radiological workflows are under immense pressure, leading to burnout and compromised diagnostic quality.
In clinical trials, where imaging endpoints are essential for roughly one-third of studies, traditional tools often lack speed and scalability, limiting their effectiveness. Fragmented AI solutions also fail to integrate seamlessly into workflows. Raidium’s technology addresses these challenges by delivering scalable, precise, and efficient insights tailored to complex cases, including whole-body diagnostics.
Introducing the “GPT of Radiology”
Founded in 2022 by Dr. Paul Hérent and Pierre Manceron, Raidium has developed the world’s first AI-native foundation model for radiology. This groundbreaking platform, referred to as the “GPT of radiology,” revolutionizes the field by functioning as an imaging biomarker factory for both clinical and research purposes.
Raidium’s platform offers advanced capabilities, including detailed 3D segmentation, automated analysis, and complex biomarker measurements—achieving speeds up to 2,500 times faster than manual methods. The AI model excels in handling intricate cases, such as detecting metastatic cancer across multiple organs or performing virtual liver biopsies for conditions like NASH.
This transformative tool enhances productivity and diagnostic accuracy, while generating automated, comprehensive reports. By integrating advanced AI with an intuitive user interface, Raidium empowers radiologists to set new benchmarks for precision and efficiency.
Building Strategic Partnerships
Since its inception, Raidium has captured the attention of leading organizations in the pharmaceutical and medical research sectors. The company has established collaborations with academic institutions in France, including AP-HP and Centre Imagerie du Nord.
Additionally, Raidium has secured contracts with pharmaceutical companies and earned a prestigious one-year mentoring program through Amgen’s Biolabs Golden Ticket initiative. These achievements underscore the growing demand for integrated imaging solutions that seamlessly bridge clinical and research applications.
Shaping the Future of Radiology
Raidium’s focus on scalable imaging biomarkers positions it to address inefficiencies in diagnostics and clinical trials. By expanding its workforce, advancing R&D, and obtaining key certifications, the company is poised to revolutionize radiological workflows with faster, more integrated solutions.
Dr. Paul Hérent, Raidium’s co-founder and CEO, emphasized the company’s mission:
“As a radiologist passionate about AI, I’ve witnessed firsthand how current solutions fail to truly support radiologists and the patients who depend on timely, accurate diagnoses. At Raidium, we aim to deliver a scalable, life-saving solution that makes radiology more precise and accessible.”
With its innovative approach and robust support from investors, Raidium is well on its way to transforming precision radiology and improving outcomes for patients worldwide.
